Navigation Links
Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Luke's Cancer Center
Date:6/3/2008

resident and CEO of Delcath Systems. "We plan to continue expanding this trial to centers throughout the United States and broadening the availability of the technology."

The Phase III Study

The Phase III study is designed to test Delcath's proprietary PHP System for the regional delivery of melphalan to the liver to treat patients with metastatic ocular and cutaneous melanoma who have unresectable tumors in the liver. The Delcath PHP System is designed to deliver significantly higher doses of anti-cancer drugs to a patient's liver while preventing entry of the drugs to the rest of the patient's circulation. This isolation limits toxicities that result from systemic chemotherapy treatments.

Patients in the Phase III trial initially are randomized into one of two treatment arms, including immediate treatment with melphalan via the Delcath PHP System or treatment with best alternative care. The study is designed to evaluate the duration of tumor response in each of the two study arms. Following guidelines established by U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA), when disease progresses in patients enrolled in the best alternative care arm of the trial, they are permitted to "cross over" and receive treatment with the Delcath PHP System. The Phase III study, which recently exceeded 33% enrollment, is expected to be completed in 2009, leading to an application to the US Food and Drug Administration (FDA) for commercial approval of the Delcath PHP System.

About Delcath Systems, Inc.

Delcath Systems is a developmental stage company testing its percutaneous perfusion technology for the isolated delivery of high doses of therapeutic and chemotherapeutic agents. The Delcath PHP System is currently being tested with the drug melphalan in Phase III and Phase II clinical trials. The Company's intellectual property portfolio currently consists of twenty-eight patents on a worldwide basis including the U.S
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
2. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
3. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
4. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
5. CoreSpine Technologies Expands Spinal Disc Site Preparation Efforts
6. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
7. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
8. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
9. PAREXEL Expands Global Clinical Pharmacology Capabilities
10. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
11. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 25, 2014 ... focused on the development of mobile diagnostic ... testing in hospital and pre-hospital settings, today ... (ISO) 13485:2003 certification.  The certification was awarded ... of the world,s leading certification bodies. ...
(Date:11/26/2014)... , Nov. 25, 2014  Breckenridge Pharmaceutical, ... a multi-product ANDA agreement with Pii (Pharmaceutics International, ... under which Breckenridge and Pii expect to develop ... of the agreement, Pii will develop, manufacture and ... distribute the products under its own label.  The ...
(Date:11/26/2014)... , Nov. 25, 2014 Halozyme Therapeutics, Inc. ... Piper Jaffray Healthcare Conference in New York ... a.m. PDT . Dr. Helen Torley , President ... The presentation will be webcast through the "Investors" section ... recording will be made available for 90 days following the ...
Breaking Medicine Technology:Nanomix Receives ISO 13485:2003 Certification 2Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with Pharmaceutics International, Inc. 2Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
(Date:11/27/2014)... “LAB.C” was featured on NewsWatch as part ... coolest technology products available to consumers. Mallory Sofastaii, a technology ... and shared with viewers the company offers a cable ... , Consumers love portability and functionality. A unique mobile ... the iPhone5 and 5S has a portable USB charger built ...
(Date:11/27/2014)... MN (PRWEB) November 27, 2014 ... of office ergonomics equipment , has announced that ... with Commercial Office Environments. The partnership will put ... office furnishings location. , In addition to having ... new dealer partnership promotes HealthPostures' products with the ...
(Date:11/27/2014)... GA (PRWEB) November 27, 2014 "The uglier, ... whole month of December is full of laughter as we ... Wilson won by making a sweater from scratch. " It ... Christmas tree, and if that weren't ridiculous enough, the Christmas ... top. , For those interested in participating this year, ...
(Date:11/27/2014)... Ethane Web Technologies, an ISO 9001: 2008 certified Internet ... discount on PPC service. The discount will be available for ... on 1 December 2014 and remain valid until midnight of ... professional working at Ethane Web Technologies says, "This is a ... big discount would make the service quite affordable for them. ...
(Date:11/27/2014)... California (PRWEB) November 27, 2014 Serious ... search for vintage 1969 Jimi Hendrix Tuscaloosa Memorial Coliseum concert ... rock bands played at the University of Alabama. Jimi ... According to Hawley, “It started with Gary Weinberger who ... working at University Programs Council. The council was responsible ...
Breaking Medicine News(10 mins):Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3Health News:Ethane Web Technologies Announces 10% Christmas Discount on PPC Service 2Health News:Serious Buyer Announces His Search For Vintage 1969 Jimi Hendrix Tuscaloosa Memorial Coliseum Concert Posters 2
... already over 194 million worldwide and the number is ... II diabetes is also known as non-insulin dependent diabetes ... endogenous insulin production and insulin requirements, leading to an ... is always some endogenous insulin production, and many patients ...
... in the form of Ascorbate was tested on nine cancer ... did not have any effect or toxicity in normal cell ... tissue culture animal cell line and almost 100% sensitive on ... from Institute of Health, Maryland has reported the finding of ...
... the latest issue of JAMA says that heart patients ... the fewer of medications. ,Heart failure affects more ... the United States and is associated with a high ... Medications shown to reduce the risk of illness and ...
... inability to conceive following 1 year of unprotected intercourse and ... ,Approximately one in every 6 couple attempting // ... has long been regarded as a women’s issue until the ... responsible in roughly half of all cases of infertility. ...
... survive cancer have about twice the rate of educational ... of cancer. The study finds children with brain ... with cranial radiation therapy (CRT) are at greatest risk ... therapies for childhood cancers have become more complex and ...
... an alternative for vaginal delivery. The procedure involves an incision in ... // in certain cases when there is a health risk to ... more popular among pregnant mothers who opt for C-sections when there ... health care delivery has to be based on the patient’s needs. ...
Cached Medicine News:Health News:Sitagliptin, Under Investigation For Type 2 Diabetes 2Health News:Heart Patients More At Risk Get Fewer Medicines 2Health News:Infertility rate in UK men increasing at an alarming rate with numbers rising over 2.5 million 2Health News:Socialization A Serious Trouble For Childhood Cancer Survivors 2Health News:Patient Choice Cesarean Section on The Rise 2
... series SV stereomicroscopes are ... type. Thanks to their ... optimally adapt to the ... is an advantage which ...
A compact stereomicroscope that is immediately ready for operation and extremely easy to use. Focused on the essential performance features, the Stemi DV4 design concept provides optimum utility....
6.3X Zoom Ratio - Boasting magnifications from 0.8X to 5X, the twin zooming objective optical system developed exclusively by Nikon provides a zoom ratio of 6.3:1. Clickstops at 1X intervals allow ob...
... Fluor 20x Water Dipping Objective is ... research where the objective is actually ... or brain slice. The objective provides ... with a numberical aperature of 0.50, ...
Medicine Products: